作者
Siow Ming Lee,Christian Klaus Jochen Schulz,K. Prabhash,B. Han,Aleksandra Szczęsna,D.L. Cortinovis,A. Rittmeyer,David Vicente Baz,Raffaele Califano,Le Tuan Anh,G. Liu,F. Cappuzzo,Jessica Reyes Contreras,Martin Reck,Youyou Hu,S. Morris,E.K. Hoeglander,M. Connors,Hans Kristian Moen Vollan,Solange Peters
摘要
In IMpower110 (NCT02409342), 1L atezo (anti–PD-L1) improved OS vs platinum-doublet chemo (PDC) in pts with PD-L1–high NSCLC and ECOG PS ≤1. However, ≥40% of NSCLC pts have poor ECOG PS (≥2) and/or substantial comorbidities, resulting in ineligibility for platinum-based chemo and most 1L clinical trials. IPSOS is a global, multicenter, open-label, randomised Phase 3 study of atezo vs single-agent chemo in pts ineligible for 1L PDC. Pts had locally advanced/metastatic NSCLC without driver mutations and were ineligible for 1L PDC due to poor PS (≥2) or comorbidities in pts aged ≥70 yr. Pts were randomised 2:1 to atezo 1200 mg IV every 3 wk or single-agent chemo (vinorelbine or gemcitabine) in 3- or 4-wk cycles. The primary endpoint was OS. Key secondary endpoints were OS rates, ORR, PFS, DOR and OS and PFS in PD-L1+ pts. Safety and health-related quality of life were also assessed. 453 pts were randomised (302 atezo; 151 chemo). Median age was 75 yr (range, 33-94), 31% were ≥80 yr, 72% were male and 83% had ECOG PS ≥2. At data cutoff (30 Apr 2022), with a median follow-up of 41.0 mo, atezo significantly improved OS vs chemo (stratified HR, 0.78; 95% CI: 0.63, 0.97; P=0.028), with a consistent benefit seen across key subgroups, including PD-L1 expression levels, PS and histology. Benefit was seen in 2-yr OS rate, ORR and DOR (Table). Gr 3/4 TRAEs occurred in 16.3% and 33.3% of pts and Gr 5 TRAEs in 1.0% and 2.7% of pts in the atezo and chemo arms, respectively. Atezo improved TTCD of chest pain vs chemo (HR, 0.51; 95% CI: 0.27, 0.97); meaningful improvements from baseline were also seen for appetite loss and cough. 1L atezo improved OS vs chemo in platinum-ineligible pts with NSCLC, with twice as many pts estimated to be alive at 2 yr when treated with atezo vs chemo. No new or unexpected safety concerns were seen in this poor prognosis population.Table: LBA11Atezo (n=302)Chemo (n=151)HRa95% CImOS (95% CI), mo10.3 (9.4, 11.9)9.2 (5.9, 11.2)0.78 (0.63, 0.97)P=0.0281-yr OS (95% CI), %43.7 (37.9, 49.4)38.6 (30.5, 46.7)–2-yr OS (95% CI), %24.3 (19.3, 29.4)12.4 (6.7, 18.0)–mPFS (95% CI), mo4.2 (3.7, 5.5)4.0 (2.9, 5.4)0.87 (0.70, 1.07)ORR (95% CI), %16.9 (12.8, 21.6)7.9 (4.2, 13.5)–mDOR (95% CI), mo14.0 (8.1, 20.3)7.8 (4.8, 9.7)–aStratified. Open table in a new tab